Usefulness of a large automated health records database in pharmacoepidemiology

Table 3 Incidence rates for diabetic events and newly introduced dialysis

	Number of events (%)	Incidence rate (per 1,000 person-years)
		Present study			JIKEI-Heart study^b		KYOTO-Heart study^c
		Total	Crude	Standardized^a	ARB	Non-ARB	ARB	Non-ARB
DM medication group Antidiabetic drug use	660 (5.0)	13,310	20.42	20.94			51.6	76.7
HbA1c 6.5% group HbA1C 6.5≤	456 (3.4)	13,310	14.07	10.85
HbA1c 6.1% group HbA1C 6.1≤	778 (5.8)	13,310	24.45	16.63
Newly introduced dialysis	365 (1.8)	20,205	7.12	5.99	1.6	1.9	1.3	3.2
Newly introduced dialysis in diabetes patient	230 (3.2)	7,085	12.32	12.08

ARB angiotensin II receptor blocker, DM diabetes mellitus
^aStandardized by age and sex using 2005 census figures
^bNewly introduced dialysis events were defined in the JIKEI-Heart study as transition to dialysis and doubling of plasma Cr levels
^cDiabetes onset events were defined in the KYOTO-Heart study as new occurrence or exacerbation of diabetes mellitus or impaired glucose tolerance, and newly introduced dialysis events were defined as transition to dialysis and doubling of plasma Cr levels

ISSN: 1347-4715